Compare AMC ENTERTAINMENT HOLDINGS, INC. (AMC) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AMC ENTERTAINMENT HOLDINGS, INC. vs Merck & Co., Inc. — how do they compare? AMC ENTERTAINMENT HOLDINGS, INC. trades at $2.46 (market cap $2.14B), while Merck & Co., Inc. trades at $132.37 (market cap $321.77B). The key difference: Merck & Co., Inc. is far larger — about 150.4× AMC ENTERTAINMENT HOLDINGS, INC.'s market cap, and Merck & Co., Inc. pays the higher dividend (2.61%). Which is the better fit depends on your goals.
| AMC | MRK | |
|---|---|---|
Market Cap | $2.14B | $321.77B |
Sector | Media | Health |
52-Week High | $3.15 | $131.84 |
52-Week Low | $0.95 | $77.60 |
Enterprise Value | $9.08B | $368.53B |
Dividend Yield | 0.11% | 2.61% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMC trades at $2.42, down 6.56% today, yet maintains a bullish technical signal with strong recent earnings beats. The company reported record Q2 2026 revenue and EBITDA, driven by surging attendance and premium screen growth. However, negative net income and substantial debt of $4.01 billion highlight financial strain. Analyst consensus is a $3.00 price target with mixed ratings (32% Buy, 46% Hold).
The outlook hinges on sustained box office recovery and cash flow improvement, with management citing a potential cash-flow breakthrough. Key risks include high leverage, dependence on film slate success, and meme-stock volatility. Upside exists if operational momentum continues, but the negative equity position warrants caution.
Merck (MRK) trades at $130.9, up 1.81% today, with a bullish technical outlook supported by moving averages and a consensus analyst price target of $140.36. Recent earnings beats and a 72.97% gross margin highlight strong profitability, while the acquisition of Terns Pharmaceuticals aims to bolster its oncology pipeline. The stock faces headwinds from a high P/E ratio of 104.34 and fluctuating cash flows.
The outlook is positive with robust fundamentals and strategic M&A, but valuation concerns and competitive pressures in pharma pose risks. Upside is likely if earnings growth continues, though investors should monitor debt levels and integration of acquisitions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AMC ENTERTAINMENT HOLDINGS, INC.
AMC Entertainment Holdings, Inc. operates as a holding company. The Company, through its subsidiaries, provides theatrical exhibition, movie screening, food distribution, online ticket booking, and other related services. AMC Entertainment offers movie theaters worldwide.
Read more on AMC →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
